Abstract

The purpose of this study was to evaluate the severity of COPD and ILD by examining the pulmonary diffusion capacity of patients with these disorders. The purpose of this research is to establish if decreased DLCO is related to an increase in morbidity. The goal of early diagnosis and effective treatment for chronic obstructive pulmonary disease and interstitial lung disease is to enhance patients' quality of life. The goal of this study is to evaluate the relationship between smoking and DLCO in COPD and ILD. Method: From January 2020 to November 2021, the Department of Pulmonary Medicine, Kakatiya Medical College, Warangal, Telangana, India, undertook a cross-sectional prospective observational study. 50 patients with chronic respiratory disorders such COPD and interstitial lung diseases met the inclusion criteria. Before the study, ethical committee approval was obtained. In their original language, subjects gave informed, written consent. Blood, CXR, HRCT, spirometry, DLCO, and 6MWT were performed after a complete history, general, and systemic examination. Result: COPD patients covered 365.45±79.26m and ILD patients 353.53±48.08m on the 6MWT. COPD patients had 95.64±1.87 pre-6MWT SpO2 and 93.18±2.83 post-6MWT. ILD patients had 96.18±1.88 pre-6MWT SpO2 and 93.12±2.78 post-6MWT. For COPD patients with 6MWT distances of 400-700 mtrs, mean DLCO levels were 71.75±21.59 and 51.10±14.41, respectively. For patients with 6MWT distances of 400-700 mtrs and <400 mtrs, mean DLCO levels were 49.317±10.90 and 62.40±9.76, respectively, in group ILD. Conclusion: Connective tissue illnesses and COPD may benefit from early lung disease detection and treatment. Pack years lower smokers' DLCO, indicating lung alveolar capillary membrane degradation. Stop smoking to preserve lung function. Since the research group has fewer anaemic individuals and normal Hb, anticipated and corrected DLCO levels are similar.

Description